Related Experiment Video
Updated: Aug 7, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression
Andrew S Luksik1, Eli Yazigi1, Pavan Shah1
1Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Abstract:
Glioblastoma (GBM) is the most common primary brain tumor, yet prognosis remains dismal with current treatment. Immunotherapeutic strategies have had limited effectiveness to date in GBM, but recent advances hold promise. One such immunotherapeutic advance is chimeric antigen receptor (CAR) T cell therapy, where autologous T cells are extracted and engineered to express a specific receptor against a GBM antigen and are then infused back into the patient. There have been numerous preclinical studies showing promising results, and several of these CAR T cell therapies are being tested in clinical trials for GBM and other brain cancers. While results in tumors such as lymphomas and diffuse intrinsic pontine gliomas have been encouraging, early results in GBM have not shown clinical benefit. Potential reasons for this are the limited number of specific antigens in GBM, their heterogenous expression, and their loss after initiating antigen-specific therapy due to immunoediting. Here, we review the current preclinical and clinical experiences with CAR T cell therapy in GBM and potential strategies to develop more effective CAR T cells for this indication.
Insights
Chimeric antigen receptor (CAR) T cell therapy shows promise for glioblastoma (GBM), but early clinical trials have yielded limited benefit. Research is exploring strategies to overcome challenges like antigen heterogeneity and loss for more effective GBM treatment.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cellular Therapy
Background:
- Glioblastoma (GBM) is an aggressive primary brain tumor with poor prognosis.
- Current treatments offer limited efficacy.
- Immunotherapy, particularly chimeric antigen receptor (CAR) T cell therapy, is a promising avenue.
Purpose of the Study:
- To review preclinical and clinical experiences with CAR T cell therapy in GBM.
- To identify challenges hindering CAR T cell efficacy in GBM.
- To discuss strategies for developing improved CAR T cell therapies for GBM.
Main Methods:
- Review of existing preclinical studies on CAR T cell therapy for GBM.
- Analysis of current clinical trial data for CAR T cell therapy in GBM.
- Discussion of immunological challenges and potential solutions.
Main Results:
- Preclinical studies show promising results for CAR T cell therapy in GBM.
- Early clinical trials in GBM have not yet demonstrated significant clinical benefit.
- Challenges include limited GBM-specific antigens, heterogeneous expression, and antigen loss.
Conclusions:
- CAR T cell therapy holds potential for GBM treatment but faces significant hurdles.
- Strategies to address antigen scarcity and heterogeneity are crucial for success.
- Further research is needed to optimize CAR T cell design and application for GBM.
